{"url_path":"/sec/mnpr/8-k/2026-06-30/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 ** **Regulation FD Disclosure**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1645469/0001437749-26-022086-index.html","accession_number":"0001437749-26-022086","cik":"0001645469","ticker":"MNPR","issuer_name":"Monopar Therapeutics","edgar_url":"https://www.sec.gov/Archives/edgar/data/1645469/0001437749-26-022086-index.html","primary_entity_key":"0001645469","primary_entity_name":"Monopar Therapeutics"},"word_count":47,"has_tables":true,"body_markdown":"**Item 7.01.** **Regulation FD Disclosure**\n\n \n\nOn June 30, 2026, Monopar Therapeutics Inc. (“Monopar”) issued a press release announcing that the U.S. Food and Drug Administration granted Rare Pediatric Disease designation to ALXN1840 (tiomolibdate choline).\n\n \n\nThe press release is furnished as Exhibit 99.1 and incorporated herein by reference."}